Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Titel:
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Auteur:
Solomon, Benjamin J Bauer, Todd M Mok, Tony S K Liu, Geoffrey Mazieres, Julien de Marinis, Filippo Goto, Yasushi Kim, Dong-Wan Wu, Yi-Long Jassem, Jacek López, Froylán López Soo, Ross A Shaw, Alice T Polli, Anna Messina, Rossella Iadeluca, Laura Toffalorio, Francesca Felip, Enriqueta